Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Shionogi Files Abuse-Deterrent Painkiller Oxycodone in Japan
December 1, 2016
- Chugai Seeks Large Vessel Vasculitis Indication for Actemra
December 1, 2016
- Signs of Growth in Prescribing SGLT-2 Inhibitors with Favorable Environment Change
November 30, 2016
- Shionogi Says UK Court Finds Its HIV Drug Patent Invalid, Set to Challenge Ruling
November 29, 2016
- Santen Eyes US Filing for Opsiria Early Next Year
November 29, 2016
- Chugai Licenses Class I PI3K Inhibitor to German Drug Maker
November 29, 2016
- Ono to Offer New Invoice Prices for Opdivo Early on to Avoid Distribution Confusion
November 29, 2016
- Prosecutors Seek 2.5 Years in Jail for Ex-Novartis Employee: Diovan Case
November 28, 2016
- Drug Makers Concerned about Cost-Effective Assessments Used for NHI Price Cuts: Survey
November 28, 2016
- Shionogi Set to Go Global with Botulinum Toxin, Gets Rights from Tokushima Univ.
November 25, 2016
- CSL Behring to Enter Japanese Hemophilia Market with Idelvion
November 25, 2016
- MSD to Distribute Bayer’s Adempas from Next Year
November 25, 2016
- Ninlaro Earns Conditional Approval in Europe: Takeda
November 25, 2016
- Gynecologist Calls for Correct Understanding of Hormonal Products
November 24, 2016
- 27 Japan Drug Makers Eke Out Profit despite Logging Lower Sales on FX, Price Cuts: Jiho Tally
November 24, 2016
- Empliciti “Extremely Promising” in the Treatment of Multiple Myeloma: Hematologist
November 24, 2016
- Fujifilm Hooks Up with China Resources in Healthcare
November 22, 2016
- Taltz Finally Makes it to Japan Market after Pricing Flap
November 22, 2016
- Empliciti, Batch of Other Drugs Go on Sale in Japan
November 21, 2016
- 3 Japan Generic Majors See Subdued Sales Rise in April-September
November 21, 2016
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…